Leuprorelin (Leuprolide) EP Impurity F serves as a reference peptide for identifying and quantifying related substances in leuprorelin preparations. Structural variation reveals how minor changes influence retention time, ionization, and folding. Researchers analyze it using LC-MS and orthogonal spectroscopic methods. Applications include impurity-specification work, process-characterization efforts, and synthetic-route refinement.
CAT No: Z10-101-196
CAS No:1872435-00-1
Synonyms/Alias:(S)-N-ethyl-1-(((S)-5-oxopyrrolidine-2-carbonyl)-D-histidyl-L-tryptophyl-D-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl)pyrrolidine-2-carboxamide;
Leuprorelin (Leuprolide) EP Impurity F is a synthetic peptide impurity structurally related to the well-characterized gonadotropin-releasing hormone (GnRH) analog, leuprorelin. As an identified impurity in the European Pharmacopoeia (EP) reference standard for leuprorelin, this compound serves as a critical analytical reference in the context of pharmaceutical quality control and peptide drug substance characterization. Its defined peptide sequence and physicochemical properties make it highly relevant for research focused on peptide impurity profiling, stability assessment, and analytical method validation within the biopharmaceutical sector.
Analytical method development: Leuprorelin-related impurities such as EP Impurity F are essential in the development and validation of chromatographic and spectrometric assays for peptide drug substances. By providing a structurally defined reference, this impurity allows researchers to optimize separation parameters, establish detection limits, and confirm the specificity of analytical methods. Its inclusion in method development ensures robust identification and quantitation of trace-level impurities in leuprorelin formulations, supporting regulatory compliance and reliable batch release testing.
Quality control and batch release testing: In the manufacture of peptide therapeutics, stringent quality control measures are required to monitor the presence and levels of process-related impurities. EP Impurity F is routinely employed as a reference standard during routine batch release and stability studies of leuprorelin active pharmaceutical ingredients and finished products. Its use enables accurate quantification of impurity content, ensuring that products meet established pharmacopoeial specifications and maintain consistent quality across production lots.
Stability studies and degradation profiling: The inclusion of defined peptide impurities such as EP Impurity F is central to forced degradation and stability-indicating studies. Researchers utilize this compound to assess the degradation pathways of leuprorelin under various stress conditions, including heat, light, and oxidative environments. By tracking the formation and persistence of this impurity, scientists gain valuable insights into the stability profile of the active ingredient and the effectiveness of formulation strategies designed to minimize degradation.
Peptide impurity characterization: Comprehensive characterization of process- and product-related impurities is essential for the development and lifecycle management of peptide pharmaceuticals. EP Impurity F serves as a model compound for elucidating the structural, chromatographic, and spectroscopic properties of leuprorelin impurities. Its use in analytical laboratories facilitates the refinement of impurity identification protocols, supports the assignment of impurity peaks, and aids in the interpretation of mass spectrometric and NMR data for related peptide species.
Reference material for regulatory submissions: The availability of well-defined peptide impurities, including EP Impurity F, is critical for the preparation of regulatory dossiers and responses to health authority queries. By incorporating this impurity into analytical comparability studies and impurity profiling reports, researchers can provide comprehensive documentation of the impurity landscape associated with leuprorelin manufacturing processes. This supports transparent communication with regulatory agencies and underpins the scientific rationale for impurity specification limits and control strategies.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More